Sign in5 stories
A Phase 1b trial testing indibulin combined with capecitabine in patients with advanced solid tumors was terminated, according to its registry record on ClinicalTrials.gov (NCT00726687, sponsor study ID IBL1005).
ClinicalTrials.gov
The phase 2 study of ZIO-101 (darinaparsin) in hematologic malignancies was stopped after enrolling 50 of a planned 70 patients, according to the registry record.
ClinicalTrials.gov
The Phase 2 study of ZIO-101 in advanced hepatocellular carcinoma was closed after 15 of a planned 40 patients were treated, with the registry citing a lack of treatment response.
ClinicalTrials.gov
The phase 2 PICASSO study stopped enrollment at 67 of a planned 100 patients after an interim look showed the primary progression-free survival endpoint had been met.
ClinicalTrials.gov
Alaunos Therapeutics closed the offering on September 21, 2026, receiving net proceeds of about $915,400.50 after fees and expenses.
SEC filing